Medicine
Ocrevus Zunovo 23000 units/920 mg per 23 mL injection
Ocrevus Zunovo 23000 units/920 mg per 23 mL injection is a prescription medicine containing Hyaluronidase (human recombinant) and Ocrelizumab for subcutaneous use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store OCREVUS ZUNOVO vials refrigerated at 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Hyaluronidase (human recombinant) and Ocrelizumab
- Brand
- Ocrevus Zunovo
- Strength
- 23000 units/920 mg per 23 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- Genentech
- Manufacturer
- Genentech
- Origin register
- US FDA, United States
- Storage
- Store OCREVUS ZUNOVO vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake. If necessary, OCREVUS ZUNOVO can be removed and placed back into the refrigerator. Unopened OCREVUS ZUNOVO vials may be stored in the original carton for a cumulative time of up to 12 hours without refrigeration at a temperature up to 25°C (77°F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 September 2024
- Identifiers
- RxCUI 2693458, 2693465DailyMed set ID b216af61-99d0-42a3-afc2-b5bf86df1ec0NDC 50242-554Application BLA761371
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 23 mL in 1 vial, single-use | 50242-554-01 | Genentech | 13 September 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Hyaluronidase (human recombinant) and Ocrelizumab is a fixed-dose combination of a CD20-directed cytolytic antibody and an endoglycosidase indicated for the treatment of relapsing forms of multiple sclerosis (MS), among other approved uses. MedsAcross supplies Hyaluronidase (human recombinant) and Ocrelizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Hyaluronidase (human recombinant) and OcrelizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ocrevus Zunovo prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
Need Ocrevus Zunovo 23000 units/920 mg per 23 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.